Cas:23153-12-0 3-Chloro-4-(methylsulfonyl)aniline manufacturer & supplier

We serve Chemical Name:3-Chloro-4-(methylsulfonyl)aniline CAS:23153-12-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-Chloro-4-(methylsulfonyl)aniline

Chemical Name:3-Chloro-4-(methylsulfonyl)aniline
CAS.NO:23153-12-0
Synonyms:3-chloro-4-(methylsulfonyl)benzenamine;3-chloro-4-(methylsulfonyl)aniline;3-chloro-4-(methylsulphonyl)aniline;3-Chloro-4-methanesulfonyl-phenylamine;3-Chlor-4-methylsulfonyl-anilin;3-Chloro-4-(methylsulfonyl)phenylamine;3-chloro-4-methanesulfonylaniline
Molecular Formula:C7H8ClNO2S
Molecular Weight:205.66200
HS Code:2921420090

Physical and Chemical Properties:
Melting point:170-171ºC
Boiling point:423.015ºC at 760 mmHg
Density:1.414g/cm3
Index of Refraction:1.584
PSA:68.54000
Exact Mass:204.99600
LogP:2.98770

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-chloro-4-(methylsulfonyl)benzenamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-chloro-4-methanesulfonylaniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-chloro-4-methanesulfonylaniline Use and application,3-Chloro-4-(methylsulfonyl)phenylamine technical grade,usp/ep/jp grade.


Related News: And, while 89 percent of seniors nationwide are now protected by COVID-19 vaccinations, less than 70 percent of the seniors living in underserved communities have been vaccinated to prevent COVID-19 infections, hospitalizations and deaths. We must stay focused on helping the most at risk.
The ChenMed primary care practices at which 100 percent of doctors and staff have received COVID-19 vaccinations include: 100 percent of Chen Senior Medical Centers in Miami; 100 percent of Dedicated Senior Medical Centers in Cincinnati, Houston, Jacksonville, Lakeland, Philadelphia, St. Louis, and Tampa Bay (Bradenton, Clearwater, Largo, Tampa, St. Petersburg);
100 percent of JenCare Senior Medical Centers in Louisville, New Orleans, and Richmond. “We’re making great progress on getting all patient-facing staff vaccinated, and our company-wide goal remains 100 percent,” explains Dr. Lane.
ChenMed has long captured monthly patient feedback using third-party vendors to capture the accurate patient experience data needed to help its primary care physicians keep nurturing outstanding relationships with members.
For the month ending June 30, 2021, the Medallia Experience Cloud survey data shows a robust ChenMed Net Promoter Score (NPS) of 82.9 — substantively higher than many best-in-industry 2021 NPS benchmarks reported by NICE Satmetrix (after collecting more than 65,000 email surveys) for iconic customer brands including Apple (60); Ritz Carlton Hotel (66); USAA (70); Alaska Airlines (71); and Costco Wholesale Corporation (80).
Medalia also surveyed 1,057 ChenMed patients in June, finding:
84 percent said it is very important for their medical care team to be COVID-19 vaccinated.
79 percent (average age 72 years) of seniors reported being more comfortable visiting a medical center when all staff is fully vaccinated.
Noting how NPS can vary by industry, region, or customer characteristics including age, income level, or time with your company, Dr. Syed reports, “Our doctors stay focused on earning trust every day by delivering truly personalized primary care. We give our patients our cell phone numbers. We encourage walk-in appointments. We really practice medicine differently, and the results are outstanding. 3,4-dichloro-1-(2,4-dichlorophenyl)-1H-pyrrole-2,5-dione manufacturers The Japanese drugmaker is injecting $126 million into its Thousand Oaks facility to boost manufacturing and support new product lines, Pacific Coast Business Times first reported. Takeda was joined by the city’s mayor, Claudia Bill-de la Peña, for a groundbreaking event on Thursday, July 22. 6-(4-amino-3-nitrophenyl)-4,4′-bis(2-methoxycarbonylethyl)-3,3′,5,5′-tetramethylpyrromethene suppliers Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial. (1α,5β,7α,8α,9β,10α,13α,14R)-1,7,14-Trihydroxykaur-16-en-15-one vendor & factory.